<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113239</url>
  </required_header>
  <id_info>
    <org_study_id>T2D+FFQ/GPAQ/Genome/Metagenome</org_study_id>
    <nct_id>NCT04113239</nct_id>
  </id_info>
  <brief_title>Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus</brief_title>
  <official_title>Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atlas Biomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atlas Biomed</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A case-control study to identify microbiome and genetic differences between healthy people
      and patients with incident type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two groups of people, one composed of healthy volunteers and the other of patients with
      incident type 2 diabetes mellitus who never received treatment for their condition, fill in
      the food frequency questionnaire and the physical activity questionnaire. DNA microarray
      genotyping is used to process the DNA samples of the participants. The data on the
      composition of the participants' gut microbiota is obtained through sequencing of their stool
      samples.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Anticipated">March 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1C</measure>
    <time_frame>Baseline</time_frame>
    <description>Glycated hemoglobin level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting blood glucose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut microbiome composition of participants</measure>
    <time_frame>Baseline</time_frame>
    <description>Bacteria abundance obtained via sequencing the DNA extracted from the stool sample</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genotypes of participants</measure>
    <time_frame>Baseline</time_frame>
    <description>Genotypes of thousands of SNPs obtained via DNA-microarray genotyping of the DNA extracted from the saliva sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical activity questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Physical Activity Questionnaire. It collects information on physical activity comprising 16 questions grouped in four domains: activity at work (1), travel to and from places (2), recreational activities (3), sedentary behaviour (4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food frequency questionnaire</measure>
    <time_frame>12 months before baseline</time_frame>
    <description>Food frequency questionnaire assesses usual intake and portion size of more than 130 foods and beverages and more than 25 dietary supplements for the last 12 months. Responses are evaluated and analysed to compile a nutritional picture for each group of subjects.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Metagenome</condition>
  <condition>Genetic Predisposition</condition>
  <arm_group>
    <arm_group_label>Diagnosed Type 2 Diabetes Mellitus</arm_group_label>
    <description>Patients with incident type 2 diabetes mellitus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Volunteers without diagnosed type 2 diabetes mellitus and who don't meet the exclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>16S rRNA gene sequencing</intervention_name>
    <description>Taking a stool sample for gut microbiome DNA sequencing</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Diagnosed Type 2 Diabetes Mellitus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA-microarray genotyping</intervention_name>
    <description>Taking a saliva sample for genotyping</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Diagnosed Type 2 Diabetes Mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers and patients with incident type 2 diabetes mellitus from Russia, Moscow
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of incident type 2 diabetes mellitus

        Exclusion Criteria:

          -  Hypoglycaemic therapy prescribed for the correction of any type of hyperglycaemia

          -  Diabetic ketoacidosis

          -  Inflammatory bowel diseases (ulcerative colitis, Crohn's disease, coeliac disease)

          -  Rheumatoid arthritis

          -  Tuberculosis

          -  Acute gastrointestinal conditions

          -  Irritable bowel syndrome

          -  Multiple intestinal polyposis

          -  Gallstone disease

          -  Acute pancreatitis

          -  Oncological diseases

          -  Serious mental disorders

          -  Recent (&lt; 6 months) antimicrobial therapy

          -  Recent (&lt; 3 months) proton pump inhibitors therapy

          -  Recent (&lt; 3 months) surgical intervention

          -  Recent (&lt; 3 weeks) use of probiotics, prebiotics, antacids, nonsteroidal
             anti-inflammatory drugs

          -  Pregnancy or breastfeeding

          -  Current alcohol/drug abuse or addiction within 12 months prior to screening

          -  Planned relocation from the study area during the study

          -  Other somatic pathologies or any factors that prevent the inclusion in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tatyana Y Demidova, MD, PhD</last_name>
    <phone>+79166700212</phone>
    <email>t.y.demidova@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladimir R Romanov</last_name>
    <phone>+79215797830</phone>
    <email>romanov@atlas.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City Clinical Hospital V.P. Demikhova</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Y Demidova, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gut Metagenetics</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Genetics</keyword>
  <keyword>Microbiome</keyword>
  <keyword>FFQ</keyword>
  <keyword>GPAQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

